Signe Risbøl Vils

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Christian Gytz Ammitzbøll, Lars Erik Bartels, J.B. Andersen et al. · ACR Open Rheumatology · 2021 · 87 citations · Full text

Medicine, Immunology, Infectious Diseases +17

Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis

Lars Erik Bartels, Christian Gytz Ammitzbøll, J.B. Andersen et al. · Rheumatology International · 2021 · 73 citations · Full text

Life Sciences, Immunology, Autoimmunity +16

Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases

Anne Troldborg, Marianne Kragh Thomsen, Lars Erik Bartels et al. · The Journal of Rheumatology · 2022 · 29 citations · Full text

Medicine, Immunology, Infectious Diseases +17

Isolation, Behavioral Changes, and Low Seroprevalence of SARS–CoV‐2 Antibodies in Patients With Systemic Lupus Erythematosus or Rheumatoid Arthritis

Christian Gytz Ammitzbøll, J.B. Andersen, Signe Risbøl Vils et al. · Arthritis Care & Research · 2021 · 17 citations · Full text

Life Sciences, Immunology, Internal Medicine +16

Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders

Christian Gytz Ammitzbøll, Marianne Kragh Thomsen, J.B. Andersen et al. · Lara D. Veeken · 2022 · 16 citations

Life Sciences, Immunology, Pharmacotherapy +17